Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma

18 Jan 2022

Abstract excerpt

OBJECTIVE: Prognostication of glioblastoma survival has become more refined due to the molecular reclassification of these tumors into isocitrate dehydrogenase (IDH) wild-type and IDH mutant. Since this molecular stratification, however, robust clinical prediction models relevant to the entire IDH wild-type glioblastoma patient population are lacking. This study aimed to provide an updated model that predicts...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ferroptosis and cancer prognosis
Share to Glioma Diagnosis and Treatment
Share to Radiomics and Machine Learning in Medical Imaging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35171829
DOI: 10.3171/2021.10.jns211261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastomaPMID 35171829Read ↗

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survivalSemantic proximity Read ↗

A prognostic model of newly diagnosed glioblastoma based on clinical characteristicsSemantic proximity Read ↗

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.Semantic proximity Read ↗

COVPRIG robustly predicts the overall survival of IDH wild-type glioblastoma and highlights METTL1+ neural-progenitor-like tumor cell in driving unfavorable outcomeSemantic proximity Read ↗

Overview of prognostic factors in adult glioma; a 10-year experience at a single institutionSemantic proximity Read ↗

Real-World Validation of the Clinical Distinctiveness of IDH-Mutant Glioblastoma in the SEER Transition Era: A Population-Based Study Integrating Machine Learning.Semantic proximity Read ↗

Survival Rate Prediction in glioblastoma Patients Using Machine learningSemantic proximity Read ↗

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant GlioblastomaSemantic proximity Read ↗

Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.Semantic proximity Read ↗

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.Semantic proximity Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

A radiomics-clinical nomogram for preoperative prediction of IDH1 mutation in primary glioblastoma multiforme.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.